Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Accumulated Depreciation & Amortization (2020 - 2023)

Historic Accumulated Depreciation & Amortization for Candel Therapeutics (CADL) over the last 4 years, with Q3 2023 value amounting to $1.8 million.

  • Candel Therapeutics' Accumulated Depreciation & Amortization rose 82000.0% to $1.8 million in Q3 2023 from the same period last year, while for Sep 2023 it was $1.8 million, marking a year-over-year increase of 82000.0%. This contributed to the annual value of $800000.0 for FY2022, which is 30000.0% up from last year.
  • According to the latest figures from Q3 2023, Candel Therapeutics' Accumulated Depreciation & Amortization is $1.8 million, which was up 82000.0% from $200000.0 recorded in Q2 2023.
  • Candel Therapeutics' 5-year Accumulated Depreciation & Amortization high stood at $1.8 million for Q3 2023, and its period low was $7000.0 during Q2 2021.
  • In the last 4 years, Candel Therapeutics' Accumulated Depreciation & Amortization had a median value of $200000.0 in 2021 and averaged $289428.6.
  • In the last 5 years, Candel Therapeutics' Accumulated Depreciation & Amortization tumbled by 6818.18% in 2021 and then skyrocketed by 275714.29% in 2022.
  • Quarter analysis of 4 years shows Candel Therapeutics' Accumulated Depreciation & Amortization stood at $91000.0 in 2020, then skyrocketed by 119.78% to $200000.0 in 2021, then soared by 300.0% to $800000.0 in 2022, then surged by 130.0% to $1.8 million in 2023.
  • Its last three reported values are $1.8 million in Q3 2023, $200000.0 for Q2 2023, and $200000.0 during Q1 2023.